Literature DB >> 29785734

Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.

Sara Raponi1, Ilaria Del Giudice1, Caterina Ilari1, Luciana Cafforio1, Monica Messina1, Luca V Cappelli1, Silvia Bonina1, Alfonso Piciocchi2, Marilisa Marinelli1, Nadia Peragine1, Paola Mariglia1, Francesca R Mauro1, Gian M Rigolin3, Francesca Rossi4, Riccardo Bomben4, Michele Dal Bo4, Giovanni Del Poeta5, Fary Diop6, Chiara Favini6, Davide Rossi7, Gianluca Gaidano6, Antonio Cuneo3, Valter Gattei4, Anna Guarini8, Robin Foá1.   

Abstract

Entities:  

Keywords:  11q deletion; BIRC3 gene; chronic lymphocytic leukaemia; droplet digital PCR; prognosis

Mesh：

Substances：

Year:  2018        PMID： 29785734     DOI： 10.1111/bjh.15405

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

Review 1.  BIRC3 and BIRC5: multi-faceted inhibitors in cancer.

Authors:  Raffaele Frazzi
Journal:  Cell Biosci       Date:  2021-01-07       Impact factor: 7.133

Review 2.  Copy Number Variation and Rearrangements Assessment in Cancer: Comparison of Droplet Digital PCR with the Current Approaches.

Authors:  Vincenza Ylenia Cusenza; Alessandra Bisagni; Monia Rinaldini; Chiara Cattani; Raffaele Frazzi
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

Review 3.  Druggable Molecular Pathways in Chronic Lymphocytic Leukemia.

Authors:  Mohammad Almasri; Marah Amer; Joseph Ghanej; Abdurraouf Mokhtar Mahmoud; Gianluca Gaidano; Riccardo Moia
Journal:  Life (Basel)       Date:  2022-02-14

Review 4.  The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment.

Authors:  Claudia Pérez-Carretero; Isabel González-Gascón-Y-Marín; Ana E Rodríguez-Vicente; Miguel Quijada-Álamo; José-Ángel Hernández-Rivas; María Hernández-Sánchez; Jesús María Hernández-Rivas
Journal:  Diagnostics (Basel)       Date:  2021-05-10

5.  Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.

Authors:  Fary Diop; Riccardo Moia; Chiara Favini; Elisa Spaccarotella; Lorenzo De Paoli; Alessio Bruscaggin; Valeria Spina; Lodovico Terzi-di-Bergamo; Francesca Arruga; Chiara Tarantelli; Clara Deambrogi; Silvia Rasi; Ramesh Adhinaveni; Andrea Patriarca; Simone Favini; Sruthi Sagiraju; Clive Jabangwe; Ahad A Kodipad; Denise Peroni; Francesca R Mauro; Ilaria Del Giudice; Francesco Forconi; Agostino Cortelezzi; Francesco Zaja; Riccardo Bomben; Francesca Maria Rossi; Carlo Visco; Annalisa Chiarenza; Gian Matteo Rigolin; Roberto Marasca; Marta Coscia; Omar Perbellini; Alessandra Tedeschi; Luca Laurenti; Marina Motta; David Donaldson; Phil Weir; Ken Mills; Patrick Thornton; Sarah Lawless; Francesco Bertoni; Giovanni Del Poeta; Antonio Cuneo; Antonia Follenzi; Valter Gattei; Renzo Luciano Boldorini; Mark Catherwood; Silvia Deaglio; Robin Foà; Gianluca Gaidano; Davide Rossi
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

6.  Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression.

Authors:  José Luis Ordóñez; Jesús-María Hernández-Rivas; Miguel Quijada-Álamo; María Hernández-Sánchez; Ana-Eugenia Rodríguez-Vicente; Claudia Pérez-Carretero; Alberto Rodríguez-Sánchez; Marta Martín-Izquierdo; Verónica Alonso-Pérez; Ignacio García-Tuñón; José María Bastida; María Jesús Vidal-Manceñido; Josefina Galende; Carlos Aguilar; José Antonio Queizán; Isabel González-Gascón Y Marín; José-Ángel Hernández-Rivas; Rocío Benito
Journal:  Blood Cancer J       Date:  2021-07-09       Impact factor: 11.037
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.